"The price of greatness is responsibility." Sir Winston Churchill


Search the IBPA



Top Menu

Menu Sidebar

IBPA Issues
About IBPA
IBPA Constitution
FAQ-s
IBPA Events
Individual Membership
Institutional Membership
IBPA Forums / Groups
Cooperation with IBPA
Links

Publications
IBPA Careers Newsletter
Past Issues
Industry Publications
Promote Yourself within the Industry
Submit Your Article

Career Center: Employers
Job Posting
Free Resume Database
Volunteers Database

Career Center: Job Seekers
Now Hiring
Submit Resume
Career Training
Nurses Careers in Biopharm
Scholarship Programs
Internship Programs
Resume Editing & Interview Coaching
Volunteer for the Industry
Download IBPA Career Info Brochure

Industry Directories and Listings
Pharmaceutical Companies
Contract Research Organizations
Professional Associations
Recruiters and Staffing Agencies
Clinical Research Centers
Consulting Companies
Education & Training Institutions
Jobs and Resume Searching Directories
Research and Development Companies
Industry Service Providers
List Your Company

Investor's Center
Offers
Calls

Contact IBPA
USAChapter
Canadian Chapter
European Chapter
Asian Chapter

Start Your Career in Biotech with IBPA Scholarship Programs
Untitled Document



Subscribe to our "Careers in the Biopharmaceutical Industry" newsletter:

Name*:

Email*:

City:

Country:

Phone:

To unsubscribe, click here

 

 

Reverse genetics

From Wikipedia, the free encyclopedia.

 

Reverse genetics is an approach to discovering the function of a gene that proceeds in the opposite direction of so called forward genetic screens that are more usual in classical genetics.

Classical and reverse genetics are alike since using either approach investigators try to deduce information from the effects of damaging or changing a genes function. By the classical approach, geneticists first look for rare individuals with an unusual phenotype and then attempt to identify the unknown faulty allele or gene. In contrast, for reverse genetics, the goal is to identifying a known gene's phenotype.

Due to the modern techniques of DNA sequencing vast amounts of genomic sequence data available and many genetic sequences are discovered in advance of other information. To learn the influence a sequence has on phenotype, or to discover its biological function, researchers can engineer a change or disruption in the DNA. After this change has been made a researcher can look for the effect of such alterations in the whole organism.

There are several different approaches to identify new alleles in a known gene.

Contents

[hide]

[edit]

 

Random deletions, insertions and point mutations

These are three similar techniques that involve creating large mutagenised populations in a similar way to forward genetic screens. These populations are generated using either chemical (point mutations), gamma radiation (deletions) or DNA insertions (insertional knockouts). These large libraries of mutants can be screened for specific changes at the gene of interest using PCR. For some organisms, such as Drosophila and Arabidopsis there are large online databases that indicate the locations of all the DNA insertions in a particular library.

[edit]

 

Directed deletions and point mutations

Site-directed mutagenesis is a sophisticated technique that can either change regulatory regions in the promoter of a gene or make subtle codon changes in the open reading frame to identify important amino residues for protein function.

Alternatively, the technique can be used to create null alleles so that the gene is not functional. For example, deletion of a gene by gene knockout can be done in some organisms, such as yeast and mice. In the case of the yeast model system directed deletions have been created in every non-essential gene in the yeast genome.

In some cases conditional alleles can be used that have normal function until the allele is activated. This is known as gene knockin. This might entail ‘knocking in’ recombinase sites (such as lox or frt sites) that will cause a deletion at the gene of interest when a specfic recombinase (such as CRE, FLP) is induced. Cre or Flp recombinases can be induced with chemical treatments, heat shock treatments or be restricted to a specific subset of tissues.

[edit]

 

Gene silencing

The discovery of gene silencing using double stranded RNA, also known as RNA interference (RNAi), and the development of gene knockdown using Morpholino oligos have made disrupting gene expression an accessible technique for many more investigators. This method is often refered to as a gene knockdown since the phenotype is rarely due to a complete loss of function.

RNAi creates a specific knockout effect without actually mutating the DNA of interest. In C. elegans, RNAi has been used to systematically interfere with the expression of most genes in the genome. RNAi acts by directing cellular systems to degrade target messenger RNA (mRNA).

While RNA interference relies on systems within the cell for efficacy (e.g. the dicer proteins, the RISC complex) a simple alternative for gene knockdown is Morpholino antisense oligos. Morpholinos bind and block access to the target mRNA without requiring the activity of cellular proteins and without necessarily accelerating mRNA degradation. Morpholinos are effective is systems ranging in complexity from cell-free translation in a test tube to humans.

[edit]

 

Interference using transgenes

A molecular genetic approach is the creation of transgenic organisms that overexpress a normal gene of interest. The resulting phenotype may reflect the normal function of the gene.

Alternatively it is possible to overexpress mutant forms of a gene that interfere with the normal (wildtype) genes function. For example, over expression of a mutant gene may result in high levels of a non-functional protein resulting in a dominant negative interaction with the wildtype protein. In this case the mutant version will out compete for the wildtype proteins partners resulting in a mutant phenotype.

Other mutant forms can result in a protein that is abnormally regulated and constitutively active (‘on’ all the time). This might be due to removing a regulatory domain or mutating a specific amino residue that is reversibly modified (by phosphorylation methylation or ubiquitination). Either change is critical for modulating protein function and often result in informative phenotypes.

Subfields of genetics
Classical genetics | Clinical genetics | Ecological genetics | Molecular genetics | Population genetics | Quantitative genetics
Related topics: Genomics | Reverse genetics



External links




Learn More About the Biopharmaceutical Industry and Clinical Research:


Category:

Logo sidebar
  • Analytical Chemistry
  • Bioinformatics
  • Biology
  • Biochemistry
  • Biotechnology
  • Biotechnology Companies
  • Cell Imaging
  • Chemistry
  • Chemists
  • Crystallography
  • Ecology
  • Environmentalism
  • Genetic Engineering
  • Genetically Modified Organisms
  • Genetics
  • Health
  • Health Care
  • Health Sciences
  • Medical Specialities
  • Medicine
  • Molecular Genetics
  • Pharmaceutical Industry
  • Pharmacy
  • Pharmacology

  • Powered by Wikipedia, the free encyclopedia. Articles were developed by IBPA volunteers.

    Logo sidebar

    A

    B

    C

    D

    E

    F

    G

    I

    K

    L

    M

    N

    P

    Q

    R

    S

    T


    Logo sidebar


    IBPA Sponsors and Active Supporters

    http://www.payoneer.com/
    Access Clinical Trials

    Access Clinical Trials
    Access Clinical Trials


    Allied Research International
    Allied Research International

    Altaspera Global Services Inc.
    Altaspera Global Services

    Financial Planning and Personal Insurance
    For Canadian Pharmaceutical Industry Executives


    Biorole Scientific Solutions
    Biorole Scientific Solutions

    CEREPROTEC INC. Development of Novel Neuroprotective Drugs
    CEREPROTEC INC. Development of Novel Neuroprotective Drugs

    Recruitment Advertising Agencies
    Recruitment Advertising Agencies

    Cellular Technology Ltd.
    Cellular Technology Ltd.

    Clinical Trial Network
    Free Database of Clinical Investigators

    ClinQua Clinical Trials Inc.
    ClinQua Clinical Trials Inc.

    Coronis Clinical Research Organization
    Coronis Clinical Research Organization

    CPIC Latin America
    CPIC Latin America

    Espoir Bridge Recruiters
    Espoir Bridge Recruiters

    Genentech
    Genentech

    ILS SA
    Independent Research and Laboratory Solutions

    Inova Health Research
    Inova Health Research, Inc.

    Kriger Research Group International
    Kriger Research Group International

    LCCT
    LCCT

    Metrics Research
    Complete Research Solutions on a Single Platform

    Pharmalef Developments
    Pharmalef Developments

    PrimeHealth Clinical Research Organization
    PrimeHealth Clinical Research Organization

    Research & Development RA SA
    Research & Development RA SA

    Scios Inc.
    Scios Inc. - Manufacturer of Health Care Products

    Scios Inc.
    Southeast Regional Research Group LLC.

    UniMR
    UniMR Clinical Research

    YM BioSciences
    YM BioSciences

    Become IBPA Sponsor
    Post Your Logo Here

    ©2004 International Biopharmaceutical Association Inc., all rights reserved
    Privacy Policy - Terms of Use

    Google